• PDF / 170,471 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 78 Downloads / 210 Views

DOWNLOAD

REPORT

1173-5503/20/0868-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

PharmacoEconomics & Outcomes News 12 Dec 2020 No. 868

1

Recommend Documents

Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia

137 69 841KB

Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leu

135 91 828KB

Inotuzumab-ozogamicin

126 2 167KB

USA proposes 2015 R&D budget of $135.4 billion

146 78 155KB

Clinical outcomes of gemtuzumab ozogamicin for relapsed acute myeloid leukemia: single-institution experience

145 79 1MB

Inotuzumab ozogamicin

133 91 167KB

Including rucaparib in US payer formulary has little budget impact

141 4 166KB

What Physicians Wished They Would Have Learned in Medical School: a Survey

141 29 268KB

Blinatumomab/inotuzumab ozogamicin

129 19 170KB

Inotuzumab-ozogamicin

177 83 168KB

The Influence of Culture on Budget Control Practices in the USA and Japan: An Empirical Study

189 57 6MB

Budget Rules and Budget Flexibility

169 61 232KB